← SynDRA
LEDIPASVIR
SynDRA canonical compound SYN0037285 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Mechanism of action | HCV inhibitor |
|---|
| Indication | hepatitis C |
|---|
| Disease area | infectious disease |
|---|
All known targets
Mechanisms of action (all sources)
- HCV inhibitor
- HCV NS5A MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ACHE
- HTR2B
- SLC6A4
- SLC6A3
- SLC6A2
- PTGS1
- PGR
- PDE4A
- PDE3A
- OPRM1
- MAOA
- KDR
- KCNH2
- HTR1A
- ADORA3
- HRH3
- HDAC6
- F2
- ESR1
- DRD3
- DRD1
- CHRM2
- CHRM1
- AR
- ADRA2A
- ADRA1A
- TBXA2R
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Anti-Infective Agents
- Antiviral Agents
- P-Glycoprotein Inhibitors
- Breast Cancer Resistance Protein Inhibitors
- Hepatitis C Virus NS5A Inhibitor
ATC classes
Cross-references
Synonyms
- HARVONI
- GS-5885
- Ledipasvir acetonate
- Ledipasvir component of harvoni
- GS 5885
- UNII-013TE6E4WV
- GS5885
- WHO 9796
- Ledipasvir (GS5885)
- 013TE6E4WV
- CHEBI:85089
- Ledipasvir [USAN:INN]
- Ledipasvir (USAN)
- SCHEMBL2706494
- SCHEMBL15116943
- CHEMBL2374220
- EX-A411
- DTXSID90154829
- MolPort-039-138-665
- HARVONI COMPONENT LEDIPASVIR
- ledipasvirum
- RefChem:798885
- DTXCID8077320
- MFCD25976756
- C49H54F2N8O6
- LEDIPASVIR ACETONATE [JAN]
- Ledipasvir [USAN]
- Ledipasvir?
- LedipasvirGS-5885
- LEDIPASVIR [MI]
- LEDIPASVIR [INN]
- Ledipasvir (USAN/INN)
- LEDIPASVIR [VANDF]
- LEDIPASVIR [WHO-DD]
- orb1688038
- LEDIPASVIR [ORANGE BOOK]
- SCHEMBL29361878
- SCHEMBL31341365
Reported adverse events
- Bradycardia
- Angioedema
- Asthenia
- Cough
- Depression
- Dizziness
- Fatigue
- Headache
- Insomnia
- Irritability
- Myalgia
- Nausea
Look up LEDIPASVIR in the interactive SynDRA portal →